The inclusion of high-penetrance HBOC-related genes such as TP53, PALB2, PTEN, CDH1, and STK11 to the NGS panel seems to be justified, even considering the low prevalence of their germline pathogenic variants, as their identification significantly alters the level of cancer prophylaxis and can substantially impact therapeutic decisions in the patient. The gene discussed is PALB2; the disease is cancer.